RFG Advisory’s Cytokinetics CYTK Stock Holding History

RFG Advisory’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-32,005	Closed	-$1.29M	–	931
2025 Q1	$1.29M	Buy	+32,005	New	+$1.47M	0.03%	352

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

RFG Advisory's CYTK Position: Q2 2025 in Review

RFG Advisory sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 32,005 shares — an estimated $1.29M sold.

RFG Advisory first reported a position in CYTK in Q1 2025 and held it in 1 quarter. The position peaked at $1.29M in Q1 2025. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

RFG Advisory reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
RFG Advisory sold 32,005 Cytokinetics shares in Q2 2025, an estimated $1.29M.
RFG Advisory first reported a position in Cytokinetics in Q1 2025 and held it in 1 quarter.
RFG Advisory's Cytokinetics position peaked at $1.29M in Q1 2025.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on RFG Advisory's 13F filing for Q2 2025, filed 28 Jul 2025.